ArticleHealthcare (Basel, Switzerland)2026
Using Genomic Data in Personalized Oncology Medicine: An Exploratory Expert-Elicitation Study with Narrative Regulatory Mapping of Regulations, Implementations, and Challenges in Saudi Arabia.
Article in Healthcare (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
objectivesPersonalized medicine represents a transformative approach to healthcare in Saudi Arabia. However, a significant research gap exists regarding the specific regulatory, implementation, and practical challenges of integrating genomic data into personalized oncology care in the Saudi context. We aimed to conduct an exploratory assessment of the current regulatory landscape, practices, and challenges related to genomic data use in personalized oncology in Saudi Arabia and to identify regulatory and practical gaps, propose actionable solutions, and outline future directions for enhancing genomic integration into cancer treatment.
methodsA mixed-methods exploratory design incorporating qualitative expert interviews and a narrative regulatory review was adopted.
resultsWe integrated qualitative insights from four subject-matter experts with evidence from a non-systematic literature review and a narrative review of regulatory documents issued by Saudi stakeholders and international authorities. The findings identified six key themes comprising (1) the emerging role of personalized medicine in cancer care, (2) current practice and Saudi genomic initiatives, (3) regulatory and policy gaps, (4) ethical and data privacy concerns, (5) infrastructure gaps and genetic testing barriers, and (6) stakeholder collaboration and data sharing, with subthemes including healthcare providers' skills, patient awareness, expert recommendations, future perspectives, and a descriptive regulatory comparison. However, these themes represent preliminary findings requiring further validation.
conclusionsWe provide preliminary insights highlighting significant challenges in integrating genomic data into personalized oncology in Saudi Arabia, emphasizing the need for a national regulatory framework, clear guidelines, robust infrastructure, and strong stakeholder collaboration. These findings offer a foundational roadmap for future research and policy development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.